Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company (Nasdaq: PVLA), will release its second quarter 2026 financial report on August 4, 2026, before the market opens. The company, based in Wayne, Pa., focuses on developing therapies for rare skin diseases and vascular malformations lacking FDA-approved treatments. Palvella will host an investor conference call at 8:30 a.m. ET on the same day to review the results and offer a corporate update.